Ferroptosis is a regulated form of non-apoptotic cell death characterized by iron-dependent accumulation of lipid peroxidation^1. Unlike apoptosis or necrosis, ferroptosis is distinguished by its unique biochemical signature: iron catalyzes the peroxidation of polyunsaturated fatty acids in membrane phospholipids, leading to membrane damage and cell death^2. This cell death pathway was formally identified in 2012 but has since been recognized as relevant to numerous pathological conditions, including neurodegenerative diseases^3.
Alzheimer's disease (AD), the most common cause of dementia worldwide, is characterized by progressive neuronal loss, accumulation of amyloid-beta (Aβ) plaques, and neurofibrillary tangles composed of hyperphosphorylated tau protein^4. Emerging evidence demonstrates that ferroptosis contributes significantly to neuronal death in AD, representing a previously underappreciated cell death mechanism that offers novel therapeutic targets for disease modification^5.
The brain requires iron for numerous essential functions including myelin production, neurotransmitter synthesis, and mitochondrial respiration^6. Iron enters the brain through the blood-brain barrier via transferrin receptor-mediated endocytosis, and neuronal iron uptake occurs through transferrin-bound iron and non-transferrin-bound iron (NTBI) via divalent metal transporter 1 (DMT1)^7.
Cellular iron homeostasis is tightly regulated by proteins including:
In Alzheimer's disease, iron homeostasis becomes profoundly disrupted, with multiple lines of evidence demonstrating brain iron accumulation^8:
| Process | Change in AD | Consequence |
|---|---|---|
| Ferroportin expression | Decreased in neurons and glia | Impaired iron export, intracellular accumulation |
| Ferritin | Increased (particularly in microglia) | Attempted iron sequestration, but insufficient |
| Transferrin | Decreased in CSF | Reduced iron clearance from brain |
| DMT1 | Increased | Enhanced ferrous iron import into neurons |
| Hepcidin | Dysregulated | Disrupted iron export signaling |
Beyond iron, copper homeostasis also plays a critical role in AD pathogenesis. Copper can induce lipid peroxidation and contribute to ferroptotic cell death. The interplay between iron and copper creates a complex redox environment that promotes neurodegeneration. Recent advances in understanding copper homeostasis and cuproptosis in central nervous system diseases provide insights into metal-dependent cell death pathways^9.
The accumulation of redox-active iron creates a pro-oxidative environment that promotes lipid peroxidation and ferroptosis^10. Iron is found in high concentrations within amyloid plaques and neurofibrillary tangles, where it may catalyze the formation of reactive oxygen species (ROS)^11. Recent research also demonstrates that microbiota-derived lysophosphatidylcholine can alleviate AD pathology by suppressing ferroptosis, highlighting the important role of metabolic factors in iron-dependent cell death^12.
The central mechanism of ferroptosis involves iron-catalyzed lipid peroxidation, particularly of phospholipids containing polyunsaturated fatty acids (PUFAs)^13:
Glutathione peroxidase 4 (GPX4) is the enzymatic core of ferroptosis prevention^14:
The cystine/glutamate antiporter (system Xc-) imports cystine for glutathione synthesis^16:
Acyl-CoA synthetase long-chain family member 4 (ACSL4) determines ferroptosis sensitivity^17:
The relationship between Aβ and iron is bidirectional and mutually reinforcing^18:
Iron is detected in amyloid plaques using post-mortem brain tissue and in vivo MRI, demonstrating the centrality of iron accumulation in AD pathology^19.
Tau pathology interacts with ferroptosis through several mechanisms^20:
Recent research has revealed that tau K677 lactylation significantly impacts ferritinophagy and ferroptosis in AD, providing a novel molecular link between tau pathology and iron-dependent cell death^21.
Mitochondria are central to both AD pathophysiology and ferroptosis^22:
Iron chelation represents a direct approach to reducing ferroptosis-inducing iron^23:
| Agent | Mechanism | Clinical Status in AD |
|---|---|---|
| Deferoxamine | Parenteral iron chelation | Historical studies showed cognitive benefit^24 |
| Deferasirox | Oral iron chelator | Phase II trials ongoing^25 |
| Clioquinol | Metal-protein attenuation | Phase II/III showed cognitive stabilization^26 |
| PBT2 | Zinc/copper/iron modulator | Phase II cognitive improvement^27 |
Direct ferroptosis inhibitors target different components of the ferroptotic cascade^28:
| Agent | Target | Evidence in AD |
|---|---|---|
| Liproxstatin-1 | 15-LOX | Preclinical show neuroprotection^29 |
| Ferrostatin-1 | Lipid ROS | Preclinical models prevent neuronal death |
| Vitamin E | Chain-breaking antioxidant | Epidemiological data support benefit^30 |
| CoQ10 | FSP1 cofactor | Mixed results in clinical trials |
Restoring GPX4 function represents a promising therapeutic strategy^31:
Recent advances highlight the importance of lipid metabolism targeting in AD treatment^34, with lipid dysregulation being a central feature of ferroptosis susceptibility. Novel ferroptosis inhibitors like Thonningianin A directly activate GPX4 to provide neuroprotection in AD models^35. Traditional Chinese medicine formulations including Kai-Xin-San have also shown anti-ferroptotic effects in AD through modulation of antioxidant pathways^36.
Rational combinations may prove more effective than single agents^37:
| Biomarker | Source | Relevance |
|---|---|---|
| Serum/CSF ferritin | Blood/CSF | Brain iron status, elevated in AD |
| Transferrin saturation | Blood | Iron availability |
| 8-OHdG | CSF/urine | Oxidative DNA damage marker |
| 4-HNE adducts | CSF/brain tissue | Lipid peroxidation products |
| CSF iron | CSF | Direct brain iron measurement |
| GPX4 activity | Blood/brain tissue | Ferroptosis susceptibility |
Quantitative susceptibility mapping (QSM) MRI can detect brain iron accumulation in vivo^38, providing:
Recent studies continue to elucidate ferroptosis in AD^39:
Key questions remain to be addressed:
Iron chelation and ferroptosis inhibition approaches have been evaluated or are under active investigation in AD clinical trials:
| Agent | Mechanism | Trial | Phase | Status |
|---|---|---|---|---|
| Deferoxamine (DFO) | Iron chelation | Historical iv/im, 1991 NEJM | N/A | Landmark study, cognitive benefit reported^24 |
| Deferasirox (Exjade) | Oral iron chelation | DEVOS trial, NCT03233009 | Phase 2 | Completed, favorable safety profile^25 |
| Clioquinol | Metal-protein attenuation | PBT2-203, PBT2-301 | Phase 2/3 | Stabilized cognition, improved executive function^26 |
| PBT2 | Zn/Cu/Fe modulator | Multiple Phase 2 | Phase 2 | Cognitive improvement on ADAS-Cog11 in APOE4 carriers^27 |
| Deferiprone | Oral iron chelation | FAIRPARK-II, NCT02655377 | Phase 2 | Tested in PD, emerging AD data |
| Vitamin E | Chain-breaking antioxidant | FIELD trial, NCT00017902 | Phase 3 | Reduced functional decline in mild-moderate AD^30 |
Pipeline programs (2024-2026):
The following biomarkers connect ferroptosis mechanisms to clinical outcomes in AD:
| Biomarker | Source | Target | Clinical Utility |
|---|---|---|---|
| Serum/CSF ferritin | Blood/CSF | Brain iron overload | Correlates with disease severity, cognitive decline, and hippocampal atrophy; useful for patient selection in iron chelation trials |
| CSF iron | CSF | Direct iron measurement | Elevated in AD vs controls; QSM-MRI provides in vivo brain iron mapping^38 |
| 4-HNE adducts | CSF/brain | Lipid peroxidation | Marker of ferroptotic activity; elevated in AD CSF; could serve as pharmacodynamic marker for ferroptosis inhibitors |
| 8-OHdG | CSF/urine | Oxidative DNA damage | Elevated in AD; reflects redox dysregulation contributing to ferroptosis |
| GPX4 activity | Blood/PBMCs | Antioxidant capacity | Reduced in AD; potential target engagement biomarker for GPX4-activating therapies |
| Transferrin saturation | Blood | Iron availability | Elevated saturation indicates pro-ferroptotic state; patient selection criterion |
| Lipid peroxides (MDA, 4-HNE) | Blood/CSF | Lipid peroxidation products | Directly reflect ferroptotic activity; therapeutic response monitoring |
| Quantitative susceptibility mapping (QSM) | MRI brain | Brain iron mapping | Non-invasive iron visualization; tracks treatment response to iron chelators^19 |
Biomarker panel strategy: Combining serum ferritin + transferrin saturation + QSM-MRI provides a comprehensive assessment of individual patient's ferroptotic burden, enabling patient selection for iron-targeted trials and monitoring of therapeutic response.
Ferroptosis inhibition and iron chelation strategies offer disease-modifying potential for AD through multiple mechanisms:
| Challenge | Impact | Mitigation Strategies |
|---|---|---|
| BBB penetration | Most iron chelators have limited CNS penetration | Develop BBB-penetrant compounds (PBT2 showed CNS penetration); use intranasal delivery; optimize dosing regimens |
| Long-term safety | Iron is essential; excessive chelation can cause anemia | Careful patient selection using iron biomarkers; monitoring hemoglobin, ferritin; dose-finding studies |
| Patient heterogeneity | Not all AD patients have elevated brain iron | Use QSM-MRI and CSF ferritin to identify iron-high subpopulation; biomarker-driven enrichment |
| Timing of intervention | Optimal window uncertain | Earlier intervention may prevent ferroptotic neuronal loss; combination with disease-modifying agents |
| Multi-target mechanisms | Ferroptosis intersects with many pathways | Combination strategies targeting iron, lipid peroxidation, and GPX4 simultaneously |